CLO20-028: Clinical Utility of Encyclopedic Tumor Analysis to Treat Breast Cancer Patients who have Failed Standard of Care Treatments

Authors:
Dadasaheb Akolkar Datar Cancer Genetics Limited, Nasik, Maharashtra, India

Search for other papers by Dadasaheb Akolkar in
Current site
Google Scholar
PubMed
Close
 PhD
,
Darshana Patil Datar Cancer Genetics Limited, Nasik, Maharashtra, India

Search for other papers by Darshana Patil in
Current site
Google Scholar
PubMed
Close
 MD
,
Anantbhushan Ranade Avinash Cancer Clinic, Pune, Maharashtra, India

Search for other papers by Anantbhushan Ranade in
Current site
Google Scholar
PubMed
Close
 MD
,
Revati Patil Datar Cancer Genetics Limited, Nasik, Maharashtra, India

Search for other papers by Revati Patil in
Current site
Google Scholar
PubMed
Close
 MD
,
Sachin Apurwa Datar Cancer Genetics Limited, Nasik, Maharashtra, India

Search for other papers by Sachin Apurwa in
Current site
Google Scholar
PubMed
Close
 MS
,
Sanket Patil Datar Cancer Genetics Limited, Nasik, Maharashtra, India

Search for other papers by Sanket Patil in
Current site
Google Scholar
PubMed
Close
 MS
,
Pradip Fulmali Datar Cancer Genetics Limited, Nasik, Maharashtra, India

Search for other papers by Pradip Fulmali in
Current site
Google Scholar
PubMed
Close
 MS
,
Pradip Devhare Datar Cancer Genetics Limited, Nasik, Maharashtra, India

Search for other papers by Pradip Devhare in
Current site
Google Scholar
PubMed
Close
 PhD
,
Navin Srivastava Datar Cancer Genetics Limited, Nasik, Maharashtra, India

Search for other papers by Navin Srivastava in
Current site
Google Scholar
PubMed
Close
 PhD
,
Ajay Srinivasan Datar Cancer Genetics Limited, Nasik, Maharashtra, India

Search for other papers by Ajay Srinivasan in
Current site
Google Scholar
PubMed
Close
 PhD
, and
Rajan Datar Datar Cancer Genetics Limited, Nasik, Maharashtra, India

Search for other papers by Rajan Datar in
Current site
Google Scholar
PubMed
Close
 BS
Full access

Background: Post failure of 3 lines of systemic treatments in breast cancers, Standard of Care guidelines recommend palliative care or clinical trials for such patients. We retrospectively evaluated the efficacy of ultra-personalized treatment in a cohort of patients (n = 27) with advanced refractory breast cancers. These patients had availed of Encyclopedic Tumor Analysis (ETA), based on which each patient received individualised organ- and label-agnostic treatment regimens. Methods: ETA was performed on freshly biopsied tumor tissue and peripheral blood. ETA interrogated gene alterations, gene expression, immunohistochemistry (IHC) in tumor tissue and in vitro chemoresistance profiling (CRP) of viable tumor cells. Findings of ETA were integrated to generate patient-specific therapy recommendations. All patients underwent whole body PET-CT and brain MRI scans prior to start of treatment. Treatment response was determined from follow-up PET-CT scans and used to calculate Objective Response Rate (ORR), Disease Control Rate (DCR) and Progression Free Survival (PFS).Results: Among the 27 patients who received personalized treatment guided by ETA, partial response (PR) was observed in 16 patients (ORR = 59.1%). At the most recent follow-up 26 patients continued to exhibit PR or Stable Disease (SD) (DCR = 96.3%). Median PFS was 115 days. There were no grade IV adverse events or any treatment related deaths. Most patients reported qualitative improvements in symptomatic and functional status. Conclusion: ETA guided treatments can offer viable treatment options in advanced refractory breast cancers yielding meaningful ORR and disease control in majority of patients.

Corresponding Author: Dadasaheb Akolkar, PhD
  • Collapse
  • Expand